To CANCER IMMUNITY Home Page

   
Latest Papers
Archives
Search for Papers
     
Contact Us

Volume 3 Supplement 1

2003

Table of Contents

Cancer Vaccine Collaborative

September 30 - October 1, 2002
New York, USA

Sponsored by the Cancer Research Institute and the Ludwig Institute for Cancer Research

Monday, September 30, 2002

 

Introduction and Overview

 

COMMENTARY
Cancer Vaccine Collaborative 2002: Opening address
Lloyd J. Old
Cancer Immunity 3 Suppl. 1 : 1 (6 February 2003) >Full text >PDF

 

Cancer Immunosurveillance / Immunoediting

 

MEETING ABSTRACT
Improving antibodies by evolution and engineering
Robert D. Schreiber, Hiroaki Ikeda, Allen Bruce, Pilar Gil, Gavin Dunn, Kathleen Sheehan, Vijay Shankaran, and Lloyd J. Old
Cancer Immunity 3 Suppl. 1 : 2 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Tumor immune surveillance in the mouse: Effectors and regulators
Mark J. Smyth and Peter MacCallum
Cancer Immunity 3 Suppl. 1 : 3 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Activating NK cell receptors providing immunity against viruses and tumors
Lewis L. Lanier
Cancer Immunity 3 Suppl. 1 : 4 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Regulatory T cells in anti-tumor immune responses
Hiroshi Shiku
Cancer Immunity 3 Suppl. 1 : 5 (6 February 2003) >Abstract >PDF

 

Cancer Antigen Discovery

 

MEETING ABSTRACT
Analysis of the B-cell repertoire against human cancers
Michael Pfreundschuh
Cancer Immunity 3 Suppl. 1 : 6 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Update on class-I restricted tumor antigens, and characterization of a novel immune escape mechanism based on tryptophan catabolism
Benoît J. Van den Eynde
Cancer Immunity 3 Suppl. 1 : 7 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Identification and characterization of target molecules for antigen-specific cancer immunotherapy
Matthew J. Scanlan
Cancer Immunity 3 Suppl. 1 : 8 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Identification of MHC class II-restricted tumor antigens and intracellular delivery of antigenic peptides into dendritic cells
Rongfu Wang
Cancer Immunity 3 Suppl. 1 : 9 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Immunophenotyping of human tumor antigens
Achim Jungbluth
Cancer Immunity 3 Suppl. 1 : 10 (6 February 2003) >Abstract >PDF

 

Monitoring the Immunological Response to Human Cancer

 

MEETING ABSTRACT
Immunological monitoring: Lessons from natural and vaccine-induced responses to Melan-A/MART-1
Jean-Charles Cerottini
Cancer Immunity 3 Suppl. 1 : 11 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Prime-boost vaccination strategies with melanoma poly-epitope constructs
Vincenzo Cerundolo
Cancer Immunity 3 Suppl. 1 : 12 (6 February 2003) >Abstract >PDF

 

Tuesday, October 1, 2002

 

Monitoring the Immunological Response to Human Cancer (continued)

 

MEETING ABSTRACT
Characterization of NY-ESO-1 and SSX gene families
Yao-Tseng Chen
Cancer Immunity 3 Suppl. 1 : 13 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Monitoring of immune responses against NY-ESO-1 in cancer patients
Elke Jäger
Cancer Immunity 3 Suppl. 1 : 14 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Comprehensive approaches to monitor CD8+ T-cell responses against tumor antigen NY-ESO-1
Sacha Gnjatic
Cancer Immunity 3 Suppl. 1 : 15 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Natural and vaccine-induced immune responses to cancer-testis antigen-derived peptides
Danila Valmori
Cancer Immunity 3 Suppl. 1 : 16 (6 February 2003) >Abstract >PDF

 

Cancer Vaccine Development

 

MEETING ABSTRACT
CTL responses of melanoma patients vaccinated with a MAGE antigen
Thierry Boon, Vaios Karanikas, Marie Marchand, Nicolas Van Baren, Christophe Lurquin, and Pierre Coulie
Cancer Immunity 3 Suppl. 1 : 17 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Cancer vaccine development in solid tumors
Alexander Knuth
Cancer Immunity 3 Suppl. 1 : 18 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
A phase 1 clinical trial of NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM® adjuvant) in patients with minimal residual disease
Jonathan S. Cebon, Ian D Davis, Phillip Parente, Weisan Chen, Mark Shackleton, Wendie Hopkins, Heather Goldie, Eugene Maraskovsky, Qiyuan Chen, Heather Jackson, Tsin Yee Tai, Grant McArthur, Peter MacCallum, Duncan MacGregor, Sue Sturrock, Simon Green, Andrew Cuthbertson, Darryl Maher, David Ryan, Michael McNamara, Debbie Drane, Lena Miloradovic, Achim Jungbluth, Gerd Ritter, Elisabeth Stockert, Yao-T. Chen, Eric Hoffman, Sacha Gnjatic, and Lloyd Old
Cancer Immunity 3 Suppl. 1 : 19 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Mechanisms of negative costimulation by CTLA-4 and its manipulation in tumor immunotherapy in mice and man
James P. Allison
Cancer Immunity 3 Suppl. 1 : 20 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Initiating immunity: Antigen presentation by dendritic cells
Ira Mellman
Cancer Immunity 3 Suppl. 1 : 21 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Modulation of immunity by dendritic cells
Nina Bhardwaj
Cancer Immunity 3 Suppl. 1 : 22 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Dendritic cell-based vaccination against cancer
Gerold Schuler
Cancer Immunity 3 Suppl. 1 : 23 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Human papillomavirus infection: Natural history and vaccine development
Luisa Lina Villa
Cancer Immunity 3 Suppl. 1 : 24 (6 February 2003) >Abstract >PDF

MEETING ABSTRACT
Immunotherapy for HPV associated pre-cancer
Ian H. Frazer, G.J. Leggatt, K. Matsumoto, R. De Kluyver, M. Quinn, J. Nicklin, J. Tan, L. Perrin, P. Ng, V. O'Connor, O. White, N. Wendt, J. Martin, S.V. Mitchell, A. McKenzie, J. Crowley, S. Edwards, and D. Maher
Cancer Immunity 3 Suppl. 1 : 25 (6 February 2003) >Abstract >PDF

 

Latest Papers
Archives
Search for Papers
Mailing List
Links
Contact Us

Copyright © 2003 by the Cancer Research Institute